NCT03495479撤回不适用
Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Changes in Prostate Specific Antigen
研究概览
简要总结
Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 72 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Localized prostate cancer suitable for active surveillance
- •Histologically confirmed adenocarcinoma of the prostate, with Gleason Score 6 or less prostate cancer. No limit in the percentage of cancer in each core or percentage of positive cores.
- •Male, 18 years or older
- •Able to swallow the soft gelatin capsule form of the drug which is ~6mm long.
- •Clinically localized prostate cancer: T1-2, NX or N0, MX or M
- •No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
- •ECOG Performance Status 0 or
- •Patient has elected Active Surveillance as preferred management plan for prostate cancer.
- •Written informed consent obtained prior to any patient participation.
- •Participant is accessible and compliant for follow-up.
- •Prostate biopsy requirements:
- •If diagnosis was within one year of baseline visit, participant must have at least one biopsy with at least 10 cores.
- •If diagnosis was more than 1 year prior to baseline visit, participant must have a minimum of 2 biopsies, one of which must be within 2 years prior to baseline visit.
- •Voiding requirements: IPSS score of at least 15 and Qmax < 15 cc/s.
- •Adequate hematopoietic function as demonstrated by:
- •hemoglobin of ≥ 9.0 g/dL without need for sustained blood transfusions
- •Platelet count ≥100,000 platelet/mm3 (100 x 109/L)
- •White Blood Cell (WBC) count ≥ 2.0 x109/L and Absolute Neutrophil Count (ANC) ≥1.5 x109/L
- •Adequate hepatobiliary function as demonstrated by:
- •Total bilirubin level within normal limits
- •Alanine aminotransferase (ALT) levels within normal limits
- •Adequate renal function as demonstrated by creatinine level within normal limits or creatinine clearance within normal limits
- •Coagulation profile (PT, PTT, INR and TCT) within normal limits
- •If of reproductive capacity, willing to use an effective double barrier method of birth control (i.e., latex condom, partner use of diaphragm, cervical cap, etc) during the study and for 30 days after the last administration of OMN54
排除标准
- •Unwillingness or inability to undergo serial prostate biopsy or MRI.
- •History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years.
- •Previous surgical intervention for BPH
- •Active uncontrolled infection, including known history of HIV, hepatitis B or C
- •Concurrent uncontrolled hypertension
- •Congestive Heart Failure
- •Hepatic disease (cirrhosis, hepatitis, hepatocellular carcinoma or liver failure of unknown etiology)
- •Renal disease (glomerulonephritis, nephropathy, polycystic kidney disease)
- •Patients requiring new treatment of BPH (either medical or surgical) are not eligible.
- •Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
- •Known hypersensitivity to any of the three botanical constituents of Aneustat™ (OMN54); soy; any of the plants belonging to the Ganodermataceae family, e.g., reishi mushroom (Ganoderma lucidum, lingzhi); any plants belonging to Labiatae or Lamiaceae families, e.g., culinary herbs including basil, mint, rosemary, sage, savory, marjoram, oregano, thyme, lavender, and perilla; or Aneustat™ (OMN54) excipients.
- •Concurrent administration, or exposure within 30 days, of:
- •Investigational drugs and devices
- •Chemotherapy
- •Radiation therapy
- •Immunotherapy
研究组 & 干预措施
OMN54 -Treated
Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
干预措施: OMN54 (Drug)
结局指标
主要结局
Changes in Prostate Specific Antigen
时间窗: 12 months
Quarterly assessment of serum Prostate Specific Antigen (PSA)
Changes in Tumor Size
时间窗: 12 months
Changes in tumor size based on semi-annual MRI
Changes in Urinary Flow
时间窗: 12 months
Quartelry assessment of patient urinary flow based on patient IPSS Questionnaire
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCastrate Sensitive Prostate CancerNCT03860987National Cancer Institute (NCI)12
已完成
2 期
Phase IIa Study of F-1311 in Patients with Prostate CancerProstate cancerJPRN-jRCT2080222723PDRadiopharma Inc.15
已完成
2 期
Phase IIb Study of F-1311 in Patients with Prostate CancerProstate CancerJPRN-jRCT2080223135PDRadiopharma Inc.56
进行中（未招募）
不适用
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.
已完成
2 期
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsProstate CancerNCT00654186Oncology Specialists, S.C.32